|
|
 |
|
Viewing report
|
|
|
|
Generics in Japan
Biopharm Knowledge Publishing, Nov 2009
The largest untapped market for generics and biosimilars
Japan is the second largest pharmaceutical market in the world. But only 5% of the market, by value, is taken by generic drugs. Like other major industrialised nations Japan has an ageing population and ageing populations take a disproportionate share of healthcare spend. For Japan the problem is very marked; it has the highest life expectancy of any major country and spends 45% of its healthcare budget on geriatric care. In 2002 Japanese healthcare insurance was on the verge of bankruptcy.
Now the government is acting to make healthcare more effective and to reduce costs. One of the methods it is using is to increase the take up of generic drugs – it aims to treble the market for generics to 15% by value by 2012, taking spend to $12 billion.
This highly detailed new report provides a complete picture of the market, its rules and regulations and how it will change over the coming years. It gives a detailed description of the hospital and GP systems, the importance of wholesalers and the likely results of the changes to the system introduced by the government, including DPC hospitals and the new prescription system.
Contents include:
- Introduction to the Japanese market
- An analysis of the Japanese pharma industry
- Wholesale and pharmacy systems
- Healthcare system and costs
- Healthcare reform
- Why generic penetration is historically low
- The impact of current and proposed reforms
- Regulations for generics
- Prospects and regulations for biosimilars
- Detailed analysis of major Japanese innovator companies
- Detailed analysis of Japanese generic companies
The report contains a detailed case study of Daiichi’s acquisition of Ranbaxy and will help you to understand:
- The size of the generic opportunity
- How the Japanese pharma market works
- The role of GPs and pharmacies
- Changes to the hospital system
- Attitudes to generics
- How pharma is reacting to the changes
Written by Mehta partners this report is essential reading for all companies involved in the Japanese market and for companies who want to take advantage of a large, fast-growing market opportunity. It aims at senior managers, company strategists and sales and marketing departments as well as providing vital information for those involved in regulatory affairs and clinical trials.
Customers who bought this item also bought
Global Biopharma Outlook 2011: Japanese Pharma
Generic Drug Market in Japan 2010
Generic Drug Market in Japan 2010
Global Biopharma Outlook 2011
Generics in Japan
Japan Generics Market Analysis
Change Is Percolating Through Japan's Pharmaceutical Markets
Market Access in Japan: New Challenges and Opportunities for the Pharmaceutical Industry
State of the Pharmaceutical Industry, 2010 - Critical Role of Midsize Pharma
Japan Pharmaceutical Market Overview Regulatory reforms will stimulate generics uptake
|
|
|
|
